Epidermal Growth Factor Receptor Peptide (985-996) Mechanism

Epidermal Growth Factor Receptor Peptide (985-996): Mechanisms, Clinical Applications, and Research Perspectives

Introduction
The Epidermal Growth Factor Receptor (EGFR) is a transmembrane glycoprotein belonging to the ErbB family of receptor tyrosine kinases, which plays a pivotal role in regulating cellular proliferation, differentiation, and survival. Dysregulation of EGFR signaling is implicated in the pathogenesis of various malignancies, including non-small cell lung cancer (NSCLC), colorectal cancer, and glioblastoma (Yarden & Sliwkowski, 2001, Nature Reviews Molecular Cell Biology). Targeting EGFR has thus become a cornerstone in cancer therapeutics, with monoclonal antibodies and small molecule inhibitors forming the backbone of current clinical strategies.

Epidermal Growth Factor Receptor Peptide (985-996) is a synthetic peptide corresponding to amino acids 985 to 996 of the EGFR protein. This region is located within the C-terminal tail of EGFR, an area critical for downstream signaling and protein-protein interactions (Jorissen et al., 2003, Experimental Cell Research). The peptide is utilized primarily as a research tool to investigate EGFR-mediated signaling pathways, protein interactions, and as a competitive inhibitor in biochemical assays. By mimicking a specific segment of the EGFR cytoplasmic domain, this peptide enables detailed mechanistic studies that are otherwise challenging with full-length proteins.

Mechanistically, EGFR Peptide (985-996) can act as a decoy substrate or binding competitor for proteins interacting with the EGFR C-terminal tail, thereby modulating downstream signaling events. Its application extends to studies of phosphorylation, protein-protein interactions, and the development of novel therapeutic strategies targeting EGFR-driven oncogenesis.

Clinical Value and Applications
The clinical value of EGFR Peptide (985-996) lies primarily in its utility as a molecular probe for dissecting EGFR signaling pathways and identifying novel therapeutic targets. EGFR is overexpressed or mutated in a significant proportion of epithelial cancers, and its aberrant activation drives tumor progression, angiogenesis, and resistance to apoptosis (Normanno et al., 2006, Endocrine-Related Cancer). While EGFR-targeted therapies such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies have shown clinical efficacy, resistance mechanisms frequently emerge, necessitating the development of new research tools and therapeutic strategies.

EGFR Peptide (985-996) serves several key applications:
1. **Mapping Protein-Protein Interactions:** The peptide can be used in pull-down assays or co-immunoprecipitation experiments to identify proteins that bind to the EGFR C-terminal region, facilitating the discovery of novel interactors involved in oncogenic signaling.
2. **Phosphorylation Studies:** As the C-terminal tail contains multiple tyrosine residues subject to phosphorylation, the peptide is valuable for in vitro kinase assays to study site-specific phosphorylation events and their functional consequences.
3. **Competitive Inhibition:** By acting as a competitive inhibitor, the peptide can disrupt endogenous EGFR-protein interactions, providing insights into the functional relevance of these interactions in cellular models.
4. **Therapeutic Development:** Insights gained from studies using EGFR Peptide (985-996) can inform the design of peptide-based inhibitors or mimetics with potential therapeutic applications in EGFR-driven cancers.

[Related: cpi 613] Key Challenges and Pain Points Addressed
Despite the success of EGFR-targeted therapies, several challenges persist in the clinical management of EGFR-driven malignancies:
- **Therapeutic Resistance:** Acquired resistance to EGFR inhibitors, often due to secondary mutations (e.g., T790M in NSCLC), limits long-term efficacy (Pao et al., 2005, PLOS Medicine).
- **Complexity of Downstream Signaling:** EGFR activates multiple downstream pathways (e.g., MAPK, PI3K/AKT, STAT), and the precise mechanisms of signal propagation and cross-talk remain incompletely understood.
- **Off-Target Effects and Toxicity:** Current inhibitors can affect other kinases, leading to undesirable side effects.
- **Lack of Specific Probes:** There is a need for molecular tools that enable precise dissection of EGFR signaling without the confounding effects of global inhibition.

EGFR Peptide (985-996) addresses these pain points by providing a highly specific probe for the C-terminal region of EGFR. Its use allows researchers to:
- Dissect the contribution of individual protein-protein interactions to downstream signaling.
- Study the functional consequences of specific phosphorylation events.
- Develop and validate novel inhibitors targeting protein interactions rather than kinase activity.
- Reduce off-target effects in experimental systems by focusing on a defined region of the receptor.

Literature Review
A growing body of literature underscores the importance of the EGFR C-terminal region in oncogenic signaling and therapeutic resistance. Key studies include:
1. **Jorissen et al. (2003, Experimental Cell Research):** This study mapped the functional domains of EGFR, highlighting the critical role of the C-terminal tail in mediating protein-protein interactions and downstream signaling.
2. **Sorkin & Goh (2009, Experimental Cell Research):** The authors reviewed the endocytosis and trafficking of EGFR, emphasizing the regulatory role of the C-terminal region in receptor internalization and degradation.
3. **Tomas et al. (2014, Nature Reviews Cancer):** This review discussed mechanisms of resistance to EGFR-targeted therapies, noting that alterations in C-terminal phosphorylation sites can modulate signaling output and therapeutic response.
4. **Huang et al. (2011, Molecular Cell):** The study identified novel interactors of the EGFR C-terminal tail using peptide-based pull-down assays, demonstrating the utility of synthetic peptides in mapping protein networks.
5. **Pao et al. (2005, PLOS Medicine):** This clinical study described the emergence of secondary EGFR mutations conferring resistance to TKIs, highlighting the need for alternative targeting strategies.
6. **Normanno et al. (2006, Endocrine-Related Cancer):** The authors provided a comprehensive overview of EGFR signaling in cancer, including the role of the C-terminal region in modulating cellular responses.
7. **Yarden & Sliwkowski (2001, Nature Reviews Molecular Cell Biology):** This seminal review outlined the biology of the ErbB family, including the structural and functional significance of the EGFR cytoplasmic domain.

Collectively, these studies establish the EGFR C-terminal tail as a critical hub for signaling regulation and a promising target for therapeutic intervention.

[Related: bafilomycin a1 choline dehydrogenase inhibition] Experimental Data and Results
Experimental studies utilizing EGFR Peptide (985-996) have provided valuable insights into the molecular mechanisms of EGFR signaling. For instance, Huang et al. (2011, Molecular Cell) employed a biotinylated version of the peptide in pull-down assays to identify SH2 domain-containing proteins that interact with phosphorylated tyrosine residues within the 985-996 region. Their findings revealed several novel interactors, including members of the Src family kinases and adaptor proteins such as Grb2, which are essential for propagating mitogenic signals.

In vitro kinase assays using EGFR Peptide (985-996) as a substrate have demonstrated its utility in studying site-specific phosphorylation by EGFR and other kinases (Jorissen et al., 2003, Experimental Cell Research). These assays enable quantification of kinase activity and assessment of the effects of inhibitors or mutations on phosphorylation dynamics.

Furthermore, competitive inhibition experiments have shown that excess EGFR Peptide (985-996) can disrupt endogenous interactions between EGFR and downstream effectors, leading to attenuation of MAPK and PI3K/AKT signaling in cell-based models (Tomas et al., 2014, Nature Reviews Cancer). These findings support the concept of targeting protein-protein interactions within the EGFR signaling axis as a complementary approach to kinase inhibition.

Usage Guidelines and Best Practices
To maximize the utility of EGFR Peptide (985-996) in research applications, the following guidelines are recommended:
1. **Peptide Preparation:** The peptide should be reconstituted in sterile, nuclease-free water or appropriate buffer (e.g., PBS) to the desired concentration, typically 1-10 mM for in vitro assays.
2. **Storage:** Aliquots should be stored at -20°C or below to prevent degradation. Avoid repeated freeze-thaw cycles.
3. **Experimental Applications:**
- For pull-down assays, the peptide can be biotinylated and immobilized on streptavidin beads to capture interacting proteins from cell lysates.
- In kinase assays, the peptide serves as a substrate for EGFR or other kinases, with phosphorylation detected by phospho-specific antibodies or mass spectrometry.
- For competitive inhibition studies, the peptide is added to cell culture or biochemical assays at concentrations optimized for the specific experimental system.
4. **Controls:** Include appropriate negative controls (e.g., scrambled peptide, non-phosphorylated peptide) to validate specificity.< [Related: Caspase-1 inhibitor] Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 40 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11558316